PDCD1 and esophageal squamous cell carcinoma: Based on the limited data, combined immunotherapy provides additional clinical benefits over standard PD‐1 inhibitor monotherapy in second‐line treatments for both immunotherapy‐naive and previously immunotherapy‐treated ESCC patients.